Trident Lifeline Ltd Stock Price Today (NSE: TLL)
Fundamental Score
Trident Lifeline Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Trident Lifeline Ltd share price today is ₹244.60, down 1.83% on NSE/BSE as of 19 June 2026. Trident Lifeline Ltd (TLL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹350.60 (Cr). The 52-week high for TLL share price is ₹328.00 and the 52-week low is ₹229.95. At a P/E ratio of 22.96x, TLL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 20.02% and a debt-to-equity ratio of 0.73.
Trident Lifeline Ltd Share Price Chart — NSE/BSE Historical Performance
Trident Lifeline Ltd share price chart: -1.19% return over the past month. 52-week high ₹328.00, 52-week low ₹229.95.
Trident Lifeline Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹249.00 | ₹249.00 | ₹244.25 | ₹244.60 | 34.80K (Cr) | |
| ₹255.75 | ₹256.00 | ₹248.05 | ₹249.15 | 28.20K (Cr) | |
| ₹248.45 | ₹253.80 | ₹245.00 | ₹249.50 | 51.60K (Cr) | |
| ₹242.00 | ₹259.00 | ₹242.00 | ₹248.55 | 39.00K (Cr) | |
| ₹250.50 | ₹252.10 | ₹249.50 | ₹249.80 | 29.40K (Cr) | |
| ₹250.00 | ₹259.80 | ₹249.90 | ₹253.45 | 39.60K (Cr) | |
| ₹248.95 | ₹248.95 | ₹248.10 | ₹248.70 | 25.20K (Cr) | |
| ₹249.05 | ₹249.75 | ₹248.70 | ₹248.75 | 25.80K (Cr) | |
| ₹251.05 | ₹251.45 | ₹246.70 | ₹250.25 | 26.40K (Cr) | |
| ₹244.00 | ₹254.00 | ₹244.00 | ₹252.80 | 29.40K (Cr) |
Trident Lifeline Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹255.75 | ₹256.00 | ₹244.25 | ₹244.60 | -4.36% | |
| ₹249.00 | ₹277.50 | ₹242.00 | ₹249.50 | +0.20% | |
| ₹306.00 | ₹306.00 | ₹240.00 | ₹250.05 | -18.28% | |
| ₹268.00 | ₹272.45 | ₹229.95 | ₹268.35 | +0.13% | |
| ₹297.25 | ₹303.00 | ₹245.10 | ₹269.00 | -9.50% | |
| ₹312.00 | ₹328.00 | ₹288.00 | ₹297.25 | -4.73% | |
| ₹307.55 | ₹324.00 | ₹265.00 | ₹310.70 | +1.02% | |
| ₹297.00 | ₹320.00 | ₹288.00 | ₹315.75 | +6.31% | |
| ₹284.35 | ₹322.85 | ₹284.35 | ₹300.00 | +5.50% | |
| ₹272.00 | ₹300.90 | ₹271.00 | ₹291.75 | +7.26% | |
| ₹307.75 | ₹307.75 | ₹261.00 | ₹297.05 | -3.48% | |
| ₹289.95 | ₹304.00 | ₹256.00 | ₹295.15 | +1.79% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap pharma play with promoter selling and high growth expectations; too risky.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Trident Lifeline has seen mixed promoter activity with Rinkal Mayurbhai Gajera selling 76,200 shares and Amit Bhupendrabhai Halvawala selling 34,800 shares in late March. Gajera's stake is now 3.34%. Trident Lifeline closed its trading window on April 1st ahead of the Q4 FY26 results.
CORE STORY (THE REAL GAME)
Trident Lifeline is being priced as a high-growth, small-cap pharma play leveraging export opportunities and domestic demand. The key is whether they can sustain the growth and manage promoter stake sales.
- Q3 FY26 revenue jumped 117.33% YoY
- Indian pharma exports are projected to reach $65 billion by 2030
- Trading window closed ahead of Q4 results
- Strong Q4 results
- New export orders
- Acquisition target
- Promoter selling
- Microcap liquidity risk
- Reliance on continued high growth
Mixed promoter activity; some selling, some buying.
Indian pharma industry projected to reach $130 billion by 2030, driven by global demand.
Free Cash Flow 5Y: ₹None Cr
Monitor Q4 results for growth sustainability. Watch for promoter activity and any regulatory concerns.
Primary Thesis Risk
Growth deceleration and promoter selling will crush the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Trident Lifeline Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Trident Lifeline Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TLL across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (20.02%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.12%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 22.96 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (48.61%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (82.43%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (5.03x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (63.10%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 8.12%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Trident Lifeline Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Trident Lifeline Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Trident Lifeline LtdTrident Lifelin...Selected✓ TLL • 543616 | 43.3/100 | ₹244.60₹245 | ₹350.60₹350.60 | 22.96Average 23.0 Average | 20.02%Excellent 20.02% Excellent | 18.12%Good 18.12% Good | 0.73Good 0.7 Good | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Trident Lifeline Ltd PE Ratio History
Historical price-to-earnings ratio for TLL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹10.22 | ₹310.70 | 30.4x |
| FY 2024 | ₹5.52 | ₹280.00 | 50.7x |
| FY 2023 | ₹6.22 | ₹188.00 | 30.2x |
| FY 2022 | ₹3.43 | ₹124.00 | 36.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Trident Lifeline Ltd Quarterly Performance
Latest quarterly metrics for TLL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
82.43%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
48.61%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Trident Lifeline Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TLL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Trident Lifeline Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Trident Lifeline Ltd (TLL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Trident Lifeline Ltd
About TLL (Trident Lifeline Ltd)
Trident Lifeline Ltd is a global pharmaceutical organization dedicated to enhancing health outcomes through the development, production, and distribution of a diverse portfolio of ...therapeutic solutions. From our state-of-the-art manufacturing facilities, we craft a wide array of formulations encompassing both conventional and innovative approaches to healthcare. Our product range extends from essential medicines addressing prevalent health challenges to specialized nutraceuticals designed to promote wellness and preventative care. TLL is driven by a commitment to uncompromising quality and rigorous adherence to international regulatory standards, ensuring that every product delivers optimal efficacy and safety to the patients who rely on us. At Trident Lifeline, we are deeply invested in expanding access to quality healthcare across the globe. We operate with a robust network of partners and distributors, allowing us to reach diverse populations with our comprehensive range of medicinal products. Our focus lies in providing tailored solutions that meet the specific needs of different markets, while remaining committed to ethical business practices and sustainable development. By continuously investing in research, development, and strategic partnerships, TLL is poised to remain at the forefront of pharmaceutical innovation, adapting to the evolving healthcare landscape and addressing unmet medical needs. Our commitment to innovation is reflected in the breadth of our offerings, which include not just traditional tablets and capsules, but also advanced delivery systems designed to improve patient adherence and therapeutic outcomes. With a comprehensive understanding of patient needs and market trends, Trident Lifeline is committed to developing and manufacturing formulations that combine efficacy, safety, and convenience. We strive to be a trusted partner in healthcare, empowering patients and providers with the tools they need to improve lives and build healthier communities.
Company Details
Key Leadership
Latest News
TLL Share Price: Frequently Asked Questions
What is the current share price of Trident Lifeline Ltd?
Trident Lifeline Ltd (TLL) trades at ₹244.60 on NSE and BSE. Market cap ₹350.60 (Cr). Educational data only.
What is the P/E ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd has a P/E of 22.96x vs industry average 31.77x.
What is the Bull Run score for Trident Lifeline Ltd?
Trident Lifeline Ltd has a Bull Run score of 43.3/100 based on 25+ financial parameters.
Does Trident Lifeline Ltd pay dividends?
Trident Lifeline Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Trident Lifeline Ltd?
Trident Lifeline Ltd has ROE of 20.02%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd has debt-to-equity of 0.73.
Is Trident Lifeline Ltd a good investment?
Bull Run gives Trident Lifeline Ltd a score of 43.3/100. This is not investment advice — consult a SEBI-registered advisor.